Neurocrine Biosciences Inc insider trading
NBIXfinancial statementsForm 4 filings on EDGAR340 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at Neurocrine Biosciences Inc bought $0 of stock in the open market, and 4 sold $3M. Officers and directors accounted for $0 of purchases and $3M of sales. The last reported transaction was an option exercise by Morrow George J on November 3, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through November 3, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $3MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
340 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Morrow George J | Director | option exercise | 7,200 | $53.64 | $386K | 17,586 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 100 | $158.18 | $16K | 17,486 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 100 | $162.05 | $16K | 17,386 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 600 | $163.71 | $98K | 16,786 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,226 | $164.74 | $202K | 15,560 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 908 | $165.71 | $150K | 14,652 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,466 | $166.77 | $244K | 13,186 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,500 | $167.72 | $252K | 11,686 | Nov 3, 2026 |
| Nov 3, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,300 | $168.53 | $219K | 10,386 | Nov 3, 2026 |
| Nov 2, 2026 | Morrow George J | Director | option exercise | 7,500 | $53.64 | $402K | 17,886 | Nov 3, 2026 |
| Nov 2, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,900 | $144.98 | $275K | 15,986 | Nov 3, 2026 |
| Nov 2, 2026 | Morrow George J | Director | open-market sale10b5-1 | 4,300 | $145.86 | $627K | 11,686 | Nov 3, 2026 |
| Nov 2, 2026 | Morrow George J | Director | open-market sale10b5-1 | 1,300 | $146.76 | $191K | 10,386 | Nov 3, 2026 |
| Nov 1, 2026 | Gano Kyle | Chief Executive Officer, Director | option exercise | 614 | $0.00 | — | 155,342 | Nov 3, 2026 |
| Nov 1, 2026 | Gano Kyle | Chief Executive Officer, Director | tax withholding | 332 | $146.10 | $49K | 155,010 | Nov 3, 2026 |
| Oct 30, 2026 | Morrow George J | Director | option exercise | 300 | $53.64 | $16K | 10,686 | Nov 3, 2026 |
| Oct 30, 2026 | Morrow George J | Director | open-market sale10b5-1 | 300 | $149.00 | $45K | 10,386 | Nov 3, 2026 |
| Sep 14, 2026 | Boyer David W. | Chief Corp. Affairs Officer | open-market sale10b5-1 | 826 | $157.45 | $130K | 8,722 | Sep 15, 2026 |
| Sep 14, 2026 | Abernethy Matt | Chief Financial Officer | open-market sale10b5-1 | 2,311 | $157.20 | $363K | 42,808 | Sep 15, 2026 |
| Sep 11, 2026 | Onyia Jude | Chief Scientific Officer | award | 3,587 | $0.00 | — | 24,583 | Sep 15, 2026 |
| Sep 11, 2026 | Onyia Jude | Chief Scientific Officer | tax withholding | 1,936 | $156.22 | $302K | 22,647 | Sep 15, 2026 |
| Sep 11, 2026 | Lippoldt Darin | Chief Legal Officer | award | 4,483 | $0.00 | — | 59,212 | Sep 15, 2026 |
| Sep 11, 2026 | Lippoldt Darin | Chief Legal Officer | tax withholding | 2,419 | $156.22 | $378K | 56,793 | Sep 15, 2026 |
| Sep 11, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | award | 3,914 | $0.00 | — | 5,393 | Sep 15, 2026 |
| Sep 11, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | tax withholding | 2,112 | $156.22 | $330K | 3,281 | Sep 15, 2026 |
| Sep 11, 2026 | Gorman Kevin Charles | Director | award | 14,343 | $0.00 | — | 525,636 | Sep 15, 2026 |
| Sep 11, 2026 | Gorman Kevin Charles | Director | tax withholding | 7,839 | $156.22 | $1M | 517,797 | Sep 15, 2026 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer, Director | award | 6,275 | $0.00 | — | 157,266 | Sep 15, 2026 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer, Director | tax withholding | 3,386 | $156.22 | $529K | 153,880 | Sep 15, 2026 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer, Director | award | 1,842 | $0.00 | — | 155,722 | Sep 15, 2026 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer, Director | tax withholding | 994 | $156.22 | $155K | 154,728 | Sep 15, 2026 |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | award | 4,483 | $0.00 | — | 20,708 | Sep 15, 2026 |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | tax withholding | 2,419 | $156.22 | $378K | 18,289 | Sep 15, 2026 |
| Sep 11, 2026 | Cooke Julie | Chief Human Resources Officer | award | 3,587 | $0.00 | — | 25,961 | Sep 15, 2026 |
| Sep 11, 2026 | Cooke Julie | Chief Human Resources Officer | tax withholding | 1,936 | $156.22 | $302K | 24,025 | Sep 15, 2026 |
| Sep 11, 2026 | Boyer David W. | Chief Corp. Affairs Officer | award | 3,587 | $0.00 | — | 11,484 | Sep 15, 2026 |
| Sep 11, 2026 | Boyer David W. | Chief Corp. Affairs Officer | tax withholding | 1,936 | $156.22 | $302K | 9,548 | Sep 15, 2026 |
| Sep 11, 2026 | Benevich Eric | Chief Commercial Officer | award | 6,275 | $0.00 | — | 70,683 | Sep 15, 2026 |
| Sep 11, 2026 | Benevich Eric | Chief Commercial Officer | tax withholding | 3,386 | $156.22 | $529K | 67,297 | Sep 15, 2026 |
| Sep 11, 2026 | Abernethy Matt | Chief Financial Officer | award | 5,020 | $0.00 | — | 47,828 | Sep 15, 2026 |
| Sep 11, 2026 | Abernethy Matt | Chief Financial Officer | tax withholding | 2,709 | $156.22 | $423K | 45,119 | Sep 15, 2026 |
| Sep 9, 2026 | Benevich Eric | Chief Commercial Officer | option exercise | 3,194 | $43.24 | $138K | 66,562 | Sep 10, 2026 |
| Sep 9, 2026 | Benevich Eric | Chief Commercial Officer | open-market sale10b5-1 | 2,154 | $154.61 | $333K | 64,408 | Sep 10, 2026 |
| Sep 2, 2026 | Sherwin Stephen A | Director | gift | 1,000 | $0.00 | — | 14,860 | Sep 3, 2026 |
| Aug 4, 2026 | Onyia Jude | Chief Scientific Officer | gift | 2,409 | $0.00 | — | 20,996 | Aug 5, 2026 |
| Jul 29, 2026 | Norwalk Leslie V | Director | option exercise | 842 | $139.43 | $117K | 2,430 | Jul 30, 2026 |
| Jul 28, 2026 | Norwalk Leslie V | Director | open-market sale10b5-1 | 1,250 | $182.01 | $228K | 1,588 | Jul 30, 2026 |
| Jul 10, 2026 | Delaet Ingrid | Chief Regulatory Officer | option exercise | 4,367 | $106.02 | $463K | 20,592 | Jul 13, 2026 |
| Jul 10, 2026 | Delaet Ingrid | Chief Regulatory Officer | open-market sale10b5-1 | 4,367 | $181.02 | $791K | 16,225 | Jul 13, 2026 |
| Jul 9, 2026 | Lippoldt Darin | Chief Legal Officer | option exercise | 10,000 | $81.49 | $815K | 64,729 | Jul 13, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Gorman Kevin Charles | Director | Sep 11, 2026 | award | 525,636 | — | $38M (1) | 1 of 1 |
| Cooke Julie | Chief Human Resources Officer | Sep 11, 2026 | award | 25,961 | — | $6M (5) | 5 of 5 |
| Gano Kyle | Chief Executive Officer, Director | Nov 1, 2026 | option exercise | 155,342 | — | $5M (3) | 2 of 3 |
| Morrow George J | Director | Nov 3, 2026 | option exercise | 17,586 | — | $4M (13) | 13 of 13 |
| Lippoldt Darin | Chief Legal Officer | Sep 11, 2026 | award | 59,212 | — | $4M (5) | 5 of 5 |
| Sherwin Stephen A | Director | Sep 2, 2026 | gift | 14,860 | — | $4M (5) | 5 of 5 |
| Delaet Ingrid | Chief Regulatory Officer | Sep 11, 2026 | award | 20,708 | — | $4M (5) | 5 of 5 |
| Onyia Jude | Chief Scientific Officer | Sep 11, 2026 | award | 24,583 | — | $3M (2) | 2 of 2 |
| Rastetter William H | Director | May 21, 2026 | option exercise | 43,678 | — | $3M (1) | 1 of 1 |
| Pops Richard F | Director | May 21, 2026 | option exercise | 37,798 | — | $2M (1) | 1 of 1 |
| Lyons Gary A | Director | May 21, 2026 | option exercise | 122,141 | — | $2M (1) | 1 of 1 |
| Norwalk Leslie V | Director | Jul 29, 2026 | option exercise | 2,430 | — | $2M (5) | 5 of 5 |
| Benevich Eric | Chief Commercial Officer | Sep 11, 2026 | award | 70,683 | — | $1M (2) | 2 of 2 |
| Boyer David W. | Chief Corp. Affairs Officer | Sep 14, 2026 | open-market sale | 8,722 | — | $739K (2) | 2 of 2 |
| Abernethy Matt | Chief Financial Officer | Sep 14, 2026 | open-market sale | 42,808 | — | $363K (1) | 1 of 1 |
| Roberts Eiry | Chief Medical Officer | Feb 14, 2025 | open-market sale | 35,640 | — | — | — |
| Keswani Sanjay Chandru | Chief Medical Officer | Sep 11, 2026 | award | 5,393 | — | — | — |
| Sharp Shalini | Director | May 21, 2026 | option exercise | 4,088 | — | — | — |
| Poon Christine A | Director | May 21, 2026 | option exercise | 4,753 | — | — | — |
| Mercier Johanna | Director | May 21, 2026 | option exercise | 6,853 | — | — | — |
Questions
Are Neurocrine Biosciences Inc insiders buying or selling?
Over the twelve months to November 3, 2026, 15 insiders at Neurocrine Biosciences Inc sold $80M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $80M. Only open-market purchases and sales are counted.
Who sold the most Neurocrine Biosciences Inc stock in the last year?
Gorman Kevin Charles (Director) sold $38M in 1 open-market sale over the twelve months to November 3, 2026.
Do Neurocrine Biosciences Inc executives sell under 10b5-1 plans?
51 of the 52 open-market sales in the last twelve months (98%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Neurocrine Biosciences Inc
- Neurocrine Biosciences Inc financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.